The ocular surface toxicity of paraquat

We describe the clinical appearance and progress of bilateral ocular chemical injury caused by paraquat, a herbicide. Paraquat is used more commonly in developing countries and it has been associated with severe and prolonged ocular surface abnormalities due to the nature of the chemical. The current concepts in managing such an injury are reviewed.

Case report

A 69 year old fruit farmer splashed a 20% solution of paraquat into both his eyes. The exposure of the right eye to the solution was more marked. The eyes were irrigated for less than 5 minutes at the time of the injury, and a formal irrigation, using Ringer’s solution for each eye, was not performed until presentation 5 hours later.

General medical history revealed that apart from controlled hypertension he was otherwise well and he had no previous history of ocular problems.

On arrival uncorrected visual acuity was 6/9 on the right and 6/12 on the left. The intraocular pressure was 14 mm Hg on the right and 19 mm Hg on the left. There was a circular 90% epithelial defect centred over the right cornea. The remaining corneal epithelium was opaque, leathery and oedematous (Fig 1). The left cornea was epithelialised in both eyes, was not performed until presentation 5 hours later.

The conjunctiva in the left eye was diffusely chemotic. There was extensive thrombosis of superficial and deep conjunctival vessels over the entire bulbar conjunctiva; however, the epithelial vessels remained intact and patent.

The left cornea had punctate epithelial erosions over most of its surface and an epithelial defect involving the inferomedial conjunctiva had just encroached onto the adjacent cornea. The conjunctiva in the left eye was also oedematous and had thrombosed vessels around the epithelial defect. Over the next few days the epithelial defect in the left eye enlarged to involve the inferonasal quadrant of the cornea although the conjunctival defect only enlarged slightly.

A severe pseudomembranous conjunctivitis developed in the right eye by the third day with fibrinous adhesions developing in the inferior fornix. Periodic glass rodding was commenced to break early symblepharon formation and the steroid was changed to non-preserved dexamethasone 1% hourly by day.

At 6 days post-injury there was evidence of epithelial healing from the margin of the epithelial defect in the inferior fornix of the right eye. Topical citrate and ascorbate were stopped and treatment was altered to non-preserved topical medication only: topical dexamethasone 1% every 2 hours, chloramphenicol four times daily, and hypromellose every 2 hours. Autologous serum tears (diluted to 20% in sterile saline solution) were also commenced 2 hourly.

Two weeks after the injury there were persistent epithelial defects in both eyes but the healing edge of conjunctival epithelium had reached the nasal limbus in the right eye. Best corrected visual acuity was 6/24 right and 6/6 left. At this stage there was no pseudomembrane present although the conjunctiva remained inflamed.

By 4 weeks after injury the ocular surface in both eyes had re-epithelialised. The cornea of the right eye at this stage was clear with no vascularisation. Visual acuity remained 6/24 on the right.

Impression cytology of both central corneas was undertaken at this point. The right cornea showed conjunctival-type epithelium with scattered goblet cells, polymorphonuclear leucocytes, and numerous apoptotic bodies. The left cornea demonstrated a corneal phenotype epithelium.

The last review was at 6 months post-injury. Uncorrected visual acuity was 6/9 in both eyes. The conjunctiva of both eyes remained minimally inflamed with mild erythema, chemosis, and subepithelial fibrosis now evident. These changes were more marked in the right eye (Fig 3). There was superficial pannus encroaching onto the right cornea predominantly superonasally. The affected area in the left eye shows subconjunctival fibrosis with vascular disorganisation and localised sceral transcluency (Fig 4). Current treatment was dexamethasone 1% twice daily in both eyes.

Comment

Paraquat is a dipyridylidium quaternary ammonium salt that acts as an indiscriminate killer of all plant life. Preparations made commercially commonly contain the related compound diquat as well as surfactants to increase distribution over the leaf and aid penetration. Toxicity in humans is thought to relate to paraquat recycling in the redox reaction (Fig 5). This depletes NADPH and interrupts cell metabolism. The reduced
We present a case of severe paraquat chemical injury to both eyes that had a good outcome from treatment. This case demonstrates a very good result from a usually devastating injury.

Preventing conjunctivalisation of the corneal surface after total loss of the limbal stem cell population remains a challenge. Therapeutic intervention may help restore a more functional surface visually. The use of intensive early antioxidant therapy followed by autologous serum tears and non-preserved ocular lubricants may have improved the outcome.

Two days before haemodialysis, the patient noticed sudden visual loss. Visual acuity was hand movement in both eyes. Anterior segment and intraocular pressure were normal. Fundus examination revealed a cherry red spot with severe retinal oedema at the macular and peripapillary area in both eyes. Disc oedema and venous engorgement were also noted in both eyes (Figs 1 and 2). The retinal manifestations were compatible with bilateral central retinal artery occlusion. Fundus fluorescein angiography was not performed because of her poor general condition.

Three days after haemodialysis, her systemic condition deteriorated with drowsiness that was proved to be cerebral vasculitis by brain computed tomography.

**References**


**Figure 5** Redox cycling reaction with paraquat.

**Figure 1** Fundus photograph of the right eye demonstrating cherry red spot with severe retinal oedema at macular and peripapillary area, disc oedema, and venous engorgement.

**Figure 2** Fundus photograph of the left eye demonstrating cherry red spot with severe retinal oedema at macular and peripapillary area, disc oedema, and venous engorgement.

**Henoch-Schönlein purpura with bilateral central retinal artery occlusion**

Henoch-Schönlein (H-S) purpura is an acute leukocytoclastic vasculitis that primarily affects children and mainly involves skin, joints, gastrointestinal tract, and kidney. Reported ophthalmic manifestations of Henoch-Schönlein purpura include episcleritis, scleritis, keratitis, anterior uveitis, and central retinal vein occlusion. However, central retinal artery occlusion, to the best of our knowledge, have not been reported. We report on a girl with H-S purpura complicated with bilateral central retinal artery occlusion.
One month later, her visual acuity was counting finger in both eyes. Fundus examination revealed a pale disc, arterial sheathing, and drusen-like RPE change at foveal area in both eyes. Six months later, her best correction visual acuity was 6/30 in the right eye, 6/60 in the left.

Comment
The dominant clinical manifestations of H-S purpura are cutaneous purpura (100%), abdominal pain (63%), gastrointestinal bleeding (33%), and nephritis (40%). In general, H-S purpura is an acute, self-limiting illness though one third of patients will have one or more recurrences of symptoms. H-S purpura was the cause of renal failure in 2% and 5% of groups of children undergoing haemodialysis in California and France, respectively. Although the aetiology of H-S purpura remains unknown, it is clear that IgA has a critical role in the immunopathogenesis. The clinical features of H-S purpura are a consequence of widespread leukocytoclastic vasculitis due to IgA deposition in vessel walls. Treatment is limited to symptomatic and supportive care. Corticosteroids are often used depending on the severity of the disease.

According to the previous reports, the ocular manifestations of H-S purpura are rare, including episcleritis, scleritis, keratitis, anterior uveitis, and central retinal vein occlusion. In this case, H-S purpura vasculitis may have an important role in the pathogenesis of bilateral central retinal artery occlusion. To our knowledge this might be the first case of H-S purpura complicated with bilateral central retinal artery occlusion in the literature.

T-T Wu, S-J Sheu, L-C Chou
Department of Ophthalmology, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan

S-J Sheu
Chung Hwa Institute of Technology, Tainan, Taiwan

Correspondence to: Tsung-Tien Wu, MD, Department of Ophthalmology, Kaohsiung Veterans General Hospital, 386 Tachung 1st Road, Kaohsiung, Taiwan 813, twu@scu.vghts.gov.tw

Accepted for publication 23 July 2001

References

Primary iris pigment epithelial hyperplasia and glaucoma
Primary iris pigment epithelial hyperplasia (PIPH) is a rare condition characterised by the presence of iris pigment epithelium on the anterior surface of the iris stroma. There are few reports that are available in the literature and they generally refer to it as congenital ectropion uveae (CEU). CEU, however, is a misnomer, since the iris pigment layer is known to be separate from the uvea. Yet, the term CEU persists in clinical use.

Primary iris pigment epithelial hyperplasia is a congenital non-progressive condition that is easily differentiated from acquired progressive ectropion uveae, the latter resulting from tractional eversion of posterior pigment layer and sphenicter muscle, secondary to glaucoma and/or uveitis.

The most common association is neurofibromatosis, though other ocular and systemic associations have been described, including a chromosomal abnormality.

This report describes two cases of primary iris pigment epithelial hyperplasia with glaucoma and reviews the available literature on this rare abnormality. In one case the presentation of glaucoma was in adolescence and in infancy in the other. Associated ocular features are described. In these two patients there were no systemic features of diagnostic significance.

Case 1
A 15 year old boy presented with occasional watering in the left eye for 4 years. There was no history of any visual disturbance.

On examination his left eye was apparently normal. The right eye was said to have been operated on by a previous surgeon. There was a history of mild photophobia by the patient which controlled the IOP.

On fundus examination there was an oblique insertion of the disc, with inferonasal crescent and an oval oblique cup involving 0.8:1 × 0.6:1 part of the disc (Fig 1, bottom right). A B-scan ultrasound of orbit confirmed that the apparent protopsis of the left eye was due to a longer axial length (24.36 mm compared with 22.60 mm in the right eye). There were two clefts at the most superotemporal area in both orbits and the IOP was 20/240 in the right eye (−1.5D sph, −4.0D cyl × 105°).

Figure 1
Case 1 with PIPH and associated abnormalities. Top left: Extensive hyperplasia of the iris pigment epithelium which overlay the stroma of the iris in an irregular manner but did not reach the angle (Fig 1, top left). The normal iris architecture was lost, but no nodules were seen. There was pigment on the anterior surface of the lens but the iris did not transilluminate. There was anisocoria of 1.5 mm, the left pupil being larger but round, regular and reacting to light. Indirect gonioscopy (Fig 1, bottom left) demonstrated an open angle with iridotrabeculodysgenesis in the form of an anterior insertion of the iris into the trabecular meshwork with excessive pigment deposition and a prominent Schwalbe’s line, this being very marked in some areas. The right eye had a fully open angle with all structures clearly seen. Intraocular pressure (IOP) on the first examination was 52 mm Hg in the left eye and 12 mm Hg in the right. On fundus examination there was an oblique insertion of the disc, with inferonasal crescent and an oval oblique cup involving 0.8:1 × 0.6:1 part of the disc (Fig 1, bottom right). A B-scan ultrasound of orbit confirmed that the apparent protopsis of the left eye was due to a longer axial length (24.36 mm compared with 22.60 mm in the right eye). There were two clefts at the most superotemporal area in both orbits and the IOP was 20/240 in the right eye (−1.5D sph, −4.0D cyl × 105°).
cyl \times 90^\circ\) and 20/20 in the left eye (−0.25D cyl \times 90^\circ). The right eye was buphthalmic with a corneal diameter of 13.0 \times 14.0 \text{ mm} (10.5 \times 11.5 \text{ mm}, left eye). The right eye had extensive hyperplasia of the iris pigment epithelium overlying the stroma of the iris in an irregular manner, but this did not reach the angle. The normal architecture of the iris was lost but there were no iris nodules. The angle was examined with a direct gonioscope and the findings were similar to that of case 1. The right pupil was 6 \text{ mm} in diameter and did not react to light and was less responsive to miotics and mydriatics.

Intraocular pressure was 27 mm Hg in the right eye, 11 mm Hg in the well formed anterior chamber was seen on fourth postoperative day but intraocular pressure was unrecordably low. The patient’s vision at 4 weeks postoperatively was 20/200.

**Comment**

In the normal iris the pigment epithelium forms a double layer that includes itself into the stroma as the pigment granules in the pigment capsule. A congenital exaggeration of this process occurs where the pigmented layer advances over the anterior surface of the iris to a varying degree. The extent to which the pigmented circumferenc is involved in PIPH is variable, but characteristically ends short of the angle. The pupil may be normal in size in some cases and larger than its counterpart in others. It may be round and reactive to light but may be oval and less reactive to light. The iris stroma is generally hypoplastic to a variable degree, with a smooth anterior surface with absence of circular concentric furrows and radial folds. The condition is usually unilateral but bilateral case has been reported.

Both the cases in this report had extensive PIPH, loss of normal iris architecture, and pupillary abnormalities.

The aetiology of the condition remains unknown but is probably due to imbalance of growth between the ectoderm and the mesoderm, usually a hyperplasia of the former. It may represent a clinical manifestation of a pathological process related to abnormal neural crest cell migration.

**References**


**Unilateral vitreous haemorrhage secondary to caudal epidural injection: a variant of Terson’s syndrome**

Terson’s syndrome is characterised by vitreous haemorrhage accompanying subarachnoid or any other form of intracranial haemorrhage. Although Litten reported vitreous haemorrhage in association with intracranial haemorrhage in 1881, it was Terson who described the syndrome in 1900. Haemorrhage in Terson’s syndrome may be contained between the internal limiting membrane and retina or extend into the vitreous cavity. Other findings include multiple preretal, intraetretal, subretinal haemorrhages, as well as macular rings and epiretinal membranes.

**Case report**

A 47 year old man with chronic back pain due to epidural adhesions (confirmed in magnetic resonance imaging (MRI)) was referred to the anaesthetic department for caudal epidural injection of steroids and saline to break up the epidural adhesions for pain relief. He received the injection through the sacral hiatus between the spinal dura and spinal canal in the caudal epidural space under general anaesthesia. Following recovery from general anaesthesia, he stated that he had lost the sight in his left eye. Ophthalmic examination at that time confirmed vision of 6/6 right eye and 6/60 left eye with no afferent pupillary defect, normal anterior segments, and the presence of a dense left vitreous haemorrhage with a normal right eye. There were no other predisposing factors for vitreous haemorrhage. Post-epidural MRI scan of brain and spinal cord was performed. There was no intracranial haemorrhage but the epidural adhesions were still noted to be present. The patient’s vision gradually improved to 6/12 over a 3 year period but because of residual severe symptomatic floaters he underwent left pars plana vitrectomy, which allowed his vision to improve to 6/6 unaided.

**Comment**

Terson proposed that intracranial haemorrhage occurred secondary to intracranial hypertension, which resulted in elevated peri-papillary capillary pressure. The most commonly cited mechanism is that elevated intracranial pressure on the arachnoidean haemorrhage is transmitted through the optic nerve sheath and obstructs intracocular venous drainage causing distortion and rupture of peripapillary and retinal capillaries resulting in significant haemorrhage in the subhyaloid space or vitreous cavity.
Severe macular pucker after retinal detachment surgery in an infant

The appearance and clinical course of rhegmatogenous retinal detachments in children are more complicated than those of adults, because the retinal detachments are generally associated with trauma or congenital anomalies. In an infant, especially, an unexpected course may develop; however, the incidence of these detachments is so low that treatment and complications have scarcely been described in the literature.

We report an infant who developed severe macular pucker after retinal detachment surgery.

Case report

A 2 week old male infant was referred with a diagnosis of bilateral congenital cataracts. The pregnancy and delivery had been uncomplicated. His mother also had had congenital anomalies, which also may underlie idiopathic retinal detachment.

Macular pucker in this infant is significantly different from that in adults. The severe posterior retinal folds may be formed by traction of the vitreous cortex on the retinal surface, rather than by residual vitreous haze and wrinkling of retina. The severe macular pucker in this infant is significantly different from that in adults with rhegmatogenous retinal detachment. However, in our case, the major component of the pucker was retinal pigment epithelium (RPE) cells, the same as in adults with rhegmatogenous retinal detachment. Cytoplasmic actin within the membrane, rather than vitreous cortex on the retinal surface, may be involved in forming strong contractile elements, which also may underlie idiopathic cases in children.

Vessels in the pucker may have originated from the adherent retina, because no residual hyaloid vessels were identified during surgery.
to treat rhegmatogenous retinal detachment in infants. Enzyme assisted vitrectomy to separate the firm vitreoretinal juncture may prevent the development of subsequent macular pucker. Frequent examinations and careful management are required even after successful reattachment surgery.

S Nishina, N Azuma
Department of Ophthalmology, National Children’s Hospital, Tokyo, Japan

Correspondence to: Noriyuki Azuma, MD, Department of Ophthalmology, National Children’s Hospital, 3-35-31 Taishido, Setagaya-ku, Tokyo, 154-8509, Japan, nazuma@nch.go.jp
Accepted for publication 16 August 2001

References

Microbial keratitis associated with extended wear of silicone hydrogel contact lenses

Traditional hydrogel soft contact lenses (SCL) have limited oxygen permeability. Recently introduced silicone hydrogel SCL have much higher oxygen transmissibility (Dk/t O2), allowing near normal oxygen supply to the cornea during extended lid closure, and are hoped by some to address most of the problems related to corneal hypoxia encountered with previous extended wear soft contact lenses. They have therefore been approved for up to 30 days of continuous wear in both Europe and Australia.

Four cases of microbial keratitis in patients who were using silicone hydrogel SCL (either CibaVision Focus Night and Day lenses (Lotrafilcon A, fluorosiloxane hydrogel) or Bausch & Lomb PureVision lenses (Balafilcon A, silicone hydrogel)) on an extended wear basis are presented. The minimum amount of continuous wear was 24 hours. All cases were treated either in private or at the corneal clinic of the Royal Victorian Eye and Ear Hospital from December 2000 to February 2001. All the patients underwent a complete ophthalmic examination by a corneal specialist. Microbiological specimens were taken from all patients via cornea scrapings and were submitted for Gram and Blankophor staining, and bacterial and fungal cultures via direct inoculation onto sheep blood agar, chocolate agar, and Sabouraud agar. Bacterial sensitivities of cultured organisms were also obtained. Where possible, the contact lenses themselves were also sent for microbial cultures.

Each case is described in brief, and a summary presented in Table 1.

Case 1
This 22 year old man presented with a 2 day history of left ocular injection, pain, photophobia, and blurred vision. He was wearing CibaVision Focus Night and Day SCL continuously for 10 days at a time, discarding the lenses after a month of use. He had swum in the sea while wearing the same lenses 2 weeks before, after which he removed the lenses and disinfected them with “Renu” multipurpose solution (boric acid, edetate disodium, poloxamine, sodium borate, sodium chloride, and polyaminopropyl biguanide), manufactured and distributed by Bausch & Lomb, Greenville, SC, USA. Continuous wear was recommenced within a few hours.

Examination revealed an uncorrected visual acuity of 3/60 in both eyes, improving to 6/12 in both eyes with pinhole. A paracentral 1 mm epithelial defect with underlying dense infiltrate was noted in the left eye with anterior chamber inflammation of +1+ cells and multiple scattered KP (Fig 1). Corneal scrapings revealed fungal elements on Gram and Blankophor staining. Cultures grew Acinetobacter species in the enrichment broth, sensitive to ciprofloxacin, chloramphenicol, and tobramycin. Penicillium was later grown on the Sabouraud agar slope. A yeast (not Candida albicans) was grown on Sabouraud agar from the left contact lens, with Penicillium species grown from the right.

Topical ciprofloxacin 0.3% was commenced hourly, after which his symptoms and signs markedly improved. The ciprofloxacin was tapered and changed to topical chloramphenicol 0.5% (Chloritis, Sigma) 8 days after presentation.

Two weeks later, the epithelial defect had resolved but significant subepithelial scarring remained. His best corrected visual acuity was 6/6 right eye and 6/7.5 left eye.

Case 2
A 16 year old boy presented with a 24 hour history of left eye grittiness, marked photophobia, and hazy vision. He was wearing PureVision SCL on a monthly continuous wear basis. He gave a history of swimming in a river in these lenses 1 week earlier, after which he removed the lenses and disinfected them with “Renu” multipurpose solution (boric acid, edetate disodium, poloxamine, sodium borate, sodium chloride, and polyaminopropyl biguanide), manufactured and distributed by Bausch & Lomb, Greenville, SC, USA. Continuous wear was recommenced within a few hours.

Examination revealed an uncorrected visual acuity of 3/60 in both eyes, improving to 6/12 in both eyes with pinhole. A paracentral 1 mm epithelial defect with underlying dense infiltrate was noted in the left eye with anterior chamber inflammation of +1+ cells and multiple scattered KP (Fig 1).

Corneal scrapings revealed fungal elements on Gram and Blankophor staining. Cultures grew Acinetobacter species in the enrichment broth, sensitive to ciprofloxacin, chloramphenicol, and tobramycin. Penicillium was later grown on the Sabouraud agar slope. A yeast (not Candida albicans) was grown on Sabouraud agar from the left contact lens, with Penicillium species grown from the right.

Topical ciprofloxacin 0.3% was commenced hourly, after which his symptoms and signs markedly improved. The ciprofloxacin was tapered and changed to topical chloramphenicol 0.5% (Chloritis, Sigma) 8 days after presentation.

Two weeks later, the epithelial defect had resolved but significant subepithelial scarring remained. His best corrected visual acuity was 6/6 right eye and 6/7.5 left eye.

Case 3
A 21 year old man was referred to MSL with a 2 day history of right eye injection, pain, photophobia, and decreased vision. He was wearing PureVision lenses on a daily wear basis, but changed to continuous wear 24 hours before the onset of his symptoms.

www.bjophthalmol.com
Table 1  Summary of case details

<table>
<thead>
<tr>
<th>Patient details</th>
<th>Case 1</th>
<th>Case 2</th>
<th>Case 3</th>
<th>Case 4</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Sex</strong></td>
<td>Male</td>
<td>Male</td>
<td>Male</td>
<td>Male</td>
</tr>
<tr>
<td><strong>Age</strong></td>
<td>22</td>
<td>16</td>
<td>21</td>
<td>17</td>
</tr>
<tr>
<td><strong>Eye</strong></td>
<td>Left</td>
<td>Left</td>
<td>Left</td>
<td>Left</td>
</tr>
<tr>
<td><strong>Refraction</strong></td>
<td>−1.75/−0.25≤+0.50</td>
<td>−4.50</td>
<td>−3.50</td>
<td>−5.00/−1.50≤+0.50</td>
</tr>
<tr>
<td><strong>Lens brand</strong></td>
<td>CibaVision Focus Night and Day</td>
<td>Bausch &amp; Lomb Pure Vision</td>
<td>Bausch &amp; Lomb Pure Vision</td>
<td>CibaVision Focus Night and Day</td>
</tr>
<tr>
<td><strong>Duration of EWSCL use</strong></td>
<td>12 months</td>
<td>12 months</td>
<td>6 weeks</td>
<td>12 months</td>
</tr>
<tr>
<td><strong>Pattern of wear</strong></td>
<td>Monthly continuous wear</td>
<td>Monthly continuous wear</td>
<td>Daily wear, changing to 24 hours continuous wear just before presentation</td>
<td>Monthly continuous wear</td>
</tr>
<tr>
<td><strong>Duration of wear</strong></td>
<td>10 days</td>
<td>Insufficient specimen, no PMN or organisms seen</td>
<td>7 days</td>
<td>No PMN, no organisms seen</td>
</tr>
<tr>
<td><strong>Microscopy</strong></td>
<td>Fungal elements on Blankophor preparation</td>
<td>No organisms on Gram stain</td>
<td>Heavy growth of Corynebacterium (sheep blood agar plate)</td>
<td>α Haemolytic streptococcus, enrichment broth</td>
</tr>
<tr>
<td><strong>Culture</strong></td>
<td>Serratia marcescens (sheep blood agar plate)</td>
<td>Acinetobacter (enrichment broth)</td>
<td>Penicillium (S. aureus agar)</td>
<td>Penicillium (sheep blood agar plate)</td>
</tr>
<tr>
<td><strong>Contact lens culture</strong></td>
<td>Serratia marcescens</td>
<td>Yeast from left lens; Penicillium from right lens</td>
<td>Not available</td>
<td>No growth</td>
</tr>
<tr>
<td><strong>Other risk factors</strong></td>
<td>Swam in lenses 2 weeks earlier</td>
<td>Swam in lenses 1 week earlier</td>
<td>Swam in a different pair of lenses 3 days earlier</td>
<td>Swam in a different pair of lenses 3 days earlier</td>
</tr>
<tr>
<td><strong>Last corrected VA (time)</strong></td>
<td>VAR=6/6−1 (2 weeks)</td>
<td>VAL=6/7.5 (8 days)</td>
<td>Unavailable</td>
<td>VAL=6/7.5 (1 week)</td>
</tr>
</tbody>
</table>

Examination revealed a visual acuity of 6/6 right eye and 6/5 left eye with his spectacle correction. Marked right eye ciliary injection and anterior chamber activity were noted with cells, flare, multiple scattered KP’s, and a small paracentral epithelial defect with underlying infiltrate.

Corneal scrapings revealed polymorphs on Gram stain (no organisms seen), and a heavy growth of *Corynebacterium* species on the sheep blood agar plate, sensitive to penicillin, ciprofloxacin, and chloramphenicol. Culture of the contact lenses was impossible as they had been discarded.

Treatment consisted of hourly topical ciprofloxacin 0.3%. Topical fluoromethalone acetate 0.1% (Flarex, Alcon, Fort Worth, TX, USA) was added four times daily after clinical improvement 24 hours later. All treatment was tapered and ceased after 2 weeks.

The patient failed to attend for any further follow up appointments but on contact by telephone stated his vision had returned to normal.

Case 4

A 17 year old presented with a 5 day history of left eye redness, irritation, photophobia, and blurred vision. He was wearing CibaVision Focus Night and Day SCL on a monthly continuous wear basis and gave a history of swimming in a river with a previous pair of lenses 3 days before the onset of symptoms.

These lenses were discarded and replaced with his current lenses the next day.

Initial treatment by the general practitioner consisted of topical chloramphenicol (0.5%) drops 2 hourly by day and chloramphenicol (1%) ointment (Chlorsig, Sigma) at night. Examination revealed a visual acuity of 6/6 right eye (with SCL) and 3/36 left eye unaided, improving to 6/18 with pinhole.

Conjunctival injection was noted in the left eye, with a 3 × 4 mm paracentral area of stromal haze and an associated area of subepithelial infiltrate. The overlying epithelium was intact.

Corneal scrapings revealed no polymorphs or organisms on Gram stain, but grew α haemolytic streptococcus from the enrichment broth sensitive to penicillin, chloramphenicol, ciprofloxacin, and neomycin.

Treatment was with hourly topical ciprofloxacin 0.3%, with tapering after 48 hours. Review 1 week later revealed a persisting subepithelial scar and a best corrected spectacle acuity of 6/7.5.

Comment

Extended wear of soft contact lenses for up to 6 days has been advocated in various forms since the 1980s with traditional hydrogel lenses. However, owing to the relatively high rates of associated microbial keratitis, extended wear of soft contact lenses has not had widespread use.

The advent of high oxygen permeability silicone hydrogel soft contact lenses has again made extended wear a viable option, as the increased oxygen permeability is thought to reduce the risk of development of a hypoxic epithelial defect, which can serve as a portal of infection. Pre-release extended wear studies did not reveal any cases of microbial keratitis but these studies were relatively small. Lenses with a Dk/t O₂ greater than 50 × 10⁻⁹ have also been shown to have a lesser affinity for *P. aeruginosa* binding during extended wear, further decreasing the risk of microbial keratitis.

Our experience suggests that extended wear with even these newer SCL is still a risk factor in the development of microbial keratitis. All four patients had central or paracentral infiltrates, with three patients presenting with an associated epithelial defect. All four patients also had a positive culture or Gram/Blankophor stain from the corneal scrape and had residual scarring after resolution of the acute episode. Although *Corynebacterium* species are considered by some to be a non-pathogenic organism, it has been described as the causative organism in several cases of microbial keratitis. We therefore feel that it is very unlikely that any of these cases represent a more benign non-infectious contact lens complication such as CLPU (contact lens induced peripheral ulcer), CLARE (contact lens induced acute red eye), or 1K (infiltrative keratitis), which are all described as being conditions that resolve after cessation of contact lens wear alone, without the development of residual corneal scarring.

Previous studies have shown that the most important risk factor for the development of microbial keratitis in soft contact lens wearers is the duration of contact lens wear, where overnight wear in particular aggravates the relative hypoxia of the cornea. However, there are other risk factors such as hypercapnia, trauma, biofilm alterations/contamination, altered corneal sensation, altered tear volume, and composition. Only hypoxia and hypercapnia should be improved by increased contact lens gas permeability.

Three of the four patients described had swum in their lenses within weeks of their presentation. This might be an important risk factor in the development of their microbial keratitis in association with their silicone hydrogel SCL (as it is with other SCL), although the organisms involved were not those typically associated with microbial keratitis from contaminated water exposure. All four of the patients were also males between the ages of 16 and 22 years. These two demographic factors have been linked to an increased risk of microbial keratitis in contact lens wearers.

Recent studies have shown that bacterial populations grown from silicone hydrogel SCL in asymptomatic wear were not statistically different in comparison with those grown from standard HEMA based SCL. This...
suggested that a silicone hydrogel SCL can still be a means of contamination in the pathogenesis of SCL microbial keratitis. Certainly, some of the lenses in this small series did grow the same organisms as the corneal lesions themselves.

Our experience supports a multifactorial causality for the development of microbial keratitis in extended SCL wearers, rather than just corneal epithelial hypoxia, particularly in high risk groups such as the four patients described where high risk behaviour is also undertaken. Further investigation needs to be done on the effects these lenses have in widespread use with the remainder of the examination being normal. Two years previously he had undergone pterygium excision of the right eye using a bare sclera technique with intraoperative application of MMC 0.02% for 3 minutes. The right eye procedure had been successful and was performed in the same institute. Three weeks after the surgery, on routine follow up scleral melting and necrosis were noted. The scleral defect was unresponsive to ocular lubricants, topical antibiotics, topical steroids, and patching. Ten weeks after the left eye pterygium excision and MMC application, he underwent autologous conjunctival graft surgery to repair the defect. Follow up 2 weeks later showed that the graft has good adaptation and re-epithelialisation was noted.

Case 3
A previously healthy 70 year old man underwent pterygium excision of the right eye using a bare sclera technique with intraoperative application of MMC 0.02% for 3 minutes. On preoperative examination, visual acuity was 6/24 partial SC in the right eye and 6/60 SC in the left, anterior segment was quiet except for a prominent white lesion 7 mm over the limbus partially covering the pupil axis in the right eye. The procedure of the right eye pterygium excision with MMC was successful and performed in the same institute. No complications or complaints were noted at the first two follow up visits, however, 3 weeks postoperatively right eye temporal scleral melting and ecrosis was noted (3 mm × 3 mm in size). Conservative topical treatment with antibiotics, topical anti-inflammatory agents, and steroids failed to improve the situation. Consequently, 8 weeks after the initial right eye surgery he underwent right eye conjunctival flap grafting over the area of scleral melting. At his last examination best corrected visual acuity was 6/36 partial, blood vessel growth was noted towards the bare sclera and re-epithelialisation with minimal staining. He is still being treated with topical antibiotics with some improvement.

References

2 Fatt I. Comparative study of some physiologically important properties of six brands of disposable hydrogel contact lenses. CLAO 1997;23:49–54.

Serious corneoscleral complications after pterygium excision with mitomycin C

The use of topical mitomycin C (MMC) to prevent recurrence after pterygium surgery is increasing since its introduction by Kunitomo and Mori in Japan, and its subsequent popularisation in the United States by Singh and associates.1 Low dose MMC (0.02%) twice daily for 5 days after the operation has been prospectively studied with long term follow up, and few serious side effects have been noted.2 Intraoperative MMC appeared to be an effective and safe adjunctive treatment of primary pterygium excision.3

Case reports

We retrospectively analysed three patients who presented at the Haemek Medical Centre, Afula, Israel with scleral melting which developed after pterygium excision between October and November 2000 with intraoperative application of MMC (0.02% for 3 minutes). The MMC was washed out immediately with an abundant amount of balanced salt solution for at least 3 minutes. During the past 10 years we performed over 300 pterygium excisions with intraoperative use of MMC in Haemek Medical Center with three cases having serious complications.

Case 1 (Fig 1)
A previously healthy 50 year old man underwent recurrent pterygium excision of the right eye using a bare sclera technique with intraoperative application of MMC 0.02% for 3 minutes, having undergone pterygium excision with MMC 10 months earlier in his right eye. Visual acuity was 6/9+5 SC. Preoperative ophthalmological examination revealed a nasal flashy wide lesion 4.5 mm over the limbus and inferior symblepharon, with the remainder of the examination being normal. He was released on the same day, following surgery at which time there were no complications. On the first (postoperative day 1) and second (postoperative day 7) follow ups no complaints or complications were noted. However, on postoperative day 30, corneal limbal perforation and iris incarceration in the wound was noted. Immediately, he underwent right eye corneal tectonic graft surgery. At his last follow up (12 weeks after the pterygium excision with MMC), the best corrected visual acuity was 6/24 CPH. The graft has good adaptation, no gap and no rejection signs.

Case 2 (Fig 2)
A previously healthy 37 year old man underwent pterygium excision of the left eye using a bare sclera technique with intraoperative application of MMC 0.02% for 3 minutes. His presenting symptoms were cosmetic only. Visual acuity was 6/60 partial SC. Preoperative ophthalmological examination revealed nasal flashy wide lesion 2.8 mm over the limbus with the remainder of the examination being normal. Two years previously he had undergone pterygium excision of the right eye using a bare sclera technique with intraoperative application of MMC 0.02% for 3 minutes. The right eye procedure had been successful and was performed in the same institute. Three weeks after the surgery, on routine follow up scleral melting and necrosis were noted. The scleral defect was unresponsive to ocular lubricants, topical antibiotics, topical steroids, and patching. Ten weeks after the left eye pterygium excision and MMC application, he underwent autologous conjunctival graft surgery to repair the defect. Follow up 2 weeks later showed that the graft has good adaptation and re-epithelialisation was noted.

Figure 1
A previously healthy 37 year old man underwent pterygium excision of the right eye using a bare sclera technique with intraoperative application of MMC 0.02% for 3 minutes. His presenting symptoms were cosmetic only. Visual acuity was 6/60 partial SC. Preoperative ophthalmological examination revealed nasal flashy wide lesion 2.8 mm over the limbus with the remainder of the examination being normal. Two years previously he had undergone pterygium excision of the right eye using a bare sclera technique with intraoperative application of MMC 0.02% for 3 minutes. The right eye procedure had been successful and was performed in the same institute. Three weeks after the surgery, on routine follow up scleral melting and necrosis were noted. The scleral defect was unresponsive to ocular lubricants, topical antibiotics, topical steroids, and patching. Ten weeks after the left eye pterygium excision and MMC application, he underwent autologous conjunctival graft surgery to repair the defect. Follow up 2 weeks later showed that the graft has good adaptation and re-epithelialisation was noted.

Figure 2
Table 1

<table>
<thead>
<tr>
<th>No</th>
<th>Age/sex/race</th>
<th>Presenting symptom</th>
<th>Clinical finding</th>
<th>Treatment</th>
<th>Preop VA v postop</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>50/M/white</td>
<td>Blurred vision, dust sensation</td>
<td>Limbal perforation with iris incarceration in the wound</td>
<td>Tectonic corneal graft</td>
<td>6/9+ SC 6/24 CPH</td>
<td>Good graft adaptation. No recurrence of pterygium after 12 weeks</td>
</tr>
<tr>
<td>2</td>
<td>37/M/white</td>
<td>Cosmetic disturbance</td>
<td>Scleral nasal melting (3 mm × 2 mm)</td>
<td>Trial at conservative topical treatment failed. Autologous conjunctival graft</td>
<td>6/9+ SC 6/12+</td>
<td>Good graft adaptation at last follow up</td>
</tr>
<tr>
<td>3</td>
<td>70/M/white</td>
<td>Pterygium covering the pupil visual axis</td>
<td>Scleral temporal melting (3 mm × 3 mm)</td>
<td>Trial at conservative topical treatment failed. Conjunctival flap</td>
<td>6/24 pt CC 6/36 pt CC</td>
<td>Blood vessels growth towards the bare sclera with re-epithelialisation. No recurrence of pterygium after 12 weeks</td>
</tr>
</tbody>
</table>

Comment

Mitomycin C is an antineoplastic antibiotic agent isolated from the fermentation filtrate of Streptomyces caespitosus. Its action is similar to alkylating agents; it alkylates and crosslinks DNA and, in addition, may generate superoxide and hydroxyl radicals in solution. It also inhibits DNA, RNA, and protein synthesis. These combined effects may result in a long-term influence on cellular proliferation.

Scleral melting occurring after pterygium surgery with adjunctive treatment has been well reported. However, no serious complications were noted in the study by Frucht-Pery and Ilzar
t with postoperative use of 0.1 mg/ml MMC twice daily for 5 days (with a mean follow up period of 15.3 months) or in intraoperative MMC treated eyes. A common element in toxicity with MMC is a relatively large cumulative dose. Therefore, most ophthalmologists believe that a single intraoperative exposure to MMC would reduce the complication rate of MMC eye drop regimen.

In the current series, all patients underwent pterygium excision in the bare sclera technique with the low concentration of 0.02% of MMC and a short application of 3 minutes. Among our patients one had corneal perforation that was treated by tectonic keratoplasty and other two had severe deep scleral melting that required conjunctival flaps or autologous grafts. Our patients were all healthy, without conditions predisposing to ulceration or poor wound healing such as Sjögren syndrome, severe keratoconjunctivitis sicca, acan rosacea, atopic keratoconjunctivitis, or herpes keratitis (Table 1). We suspected that the MMC concentration was not appropriate during that period. We checked the concentration and it was difficult to obtain precise results after a waiting period, owing to the degradation of the material.

This report raises serious questions regarding routine use of MMC. Recently, some investigators have evaluated the safety and effectiveness of low dose MMC (0.02%) for an even shorter time (30 seconds). All ophthalmologists should be aware of the possibility of vision threatening complications and avoid routine and broad use of mitomycin in all fields.

References


Extrasceral extension of a choroidal melanoma after argon photocoagulation and transscleral thermotherapy

The optimal management of small posterior choroidal melanomas remains controversial, especially for tumours located near the optic disc and fovea. Although with increasing rarity, argon laser photocoagulation continues to be used in the primary treatment of small tumours, despite data suggesting that other therapeutic methods may be more successful. More recently, transscleral thermotherapy (TTT) has emerged as a therapeutic option for the primary treatment of small choroidal melanomas. Initial results are promising, but like any new treatments, more widespread use and longer follow up are needed for a thorough assessment of its efficacy. As a cautionary reminder that additional study is required to define the potential complications of these treatments, we present a case of choroidal melanoma in which treatment with primary argon photocoagulation followed by TTT was associated with extrasceral extension of the tumour.

Case report

A 38 year old woman presented with decreased visual acuity in her right eye. An ophthalmologist noted a pigmented choroidal lesion with associated subretinal fluid. The lesion was initially treated with argon laser photocoagulation, but within the decision was made to re-treat the lesion with TTT. Over the next 7 months, visual acuity deteriorated to 20/200. The lesion exhibited persistent elevation and subretinal fluid. By ultrasound, a change in the retrolental echogenicity was observed, precipitating referral to an ophthalmic oncologist whereupon a diagnosis of choroidal melanoma with extrascaleral extension was made. The patient was then referred to UCSF for consideration of proton beam therapy. On examination, all abnormal findings were confined to the right eye. The patient’s visual acuity was counting fingers at 2 feet. Funduscopic examination revealed a raised pigmented tumour centred on the fovea, measuring 7 mm vertically by 10 mm horizontally, extending to within 2.3 mm of the disc. Subretinal fluid was present and extended over the nasal aspect of the tumour (Fig 1A). A flat

Figure 1 (A) Fundus photograph of the right eye demonstrating a pigmented choroidal tumour in the macular region with an area nasally exhibiting orange pigment on its surface. There is associated subretinal fluid extending nasally. (B) Fluorescein angiography demonstrates irregular choroidal vessels within the tumour that are bright in the early arterial phase and show late leakage with punctate hot spots.
naevus 2 mm in diameter was also noted infero-externally (not shown). Fluorescein angiography was remarkable for an irregular plexus of choroidal vessels within the tumour noted in the early arterio-venous phase, mid-phase leakage from retinal veins overlying the tumour, and late leakage with punctate hot spots at the tumour margin (Fig 1B). B-scan ultrasound revealed choroidal excavation, an acoustic quiet zone, and orbital shadowing (Fig 2A). A-scan demonstrated spontaneous pulsation, low to medium internal reflectivity, and a sharp posterior spike (Fig 2B). The intraocular thickness was 3.0 mm, with 7.7 mm of extraocular extension. These findings are consistent with choroidal melanoma with posterior extraocular extension. Systematic evaluation revealed no signs of metastasis. The potential for orbital contamination by tumour made foveal therapy by proton beam a less desirable alternative. Therefore, enucleation with en bloc resection of the extraocular tumour was recommended and subsequently performed. Pathological examination confirmed the diagnosis of malignant choroidal melanoma, mixed cell type, with extensive extraocular extension and focal vascular invasion. The patient elected to undergo adjuvant post-surgical external beam irradiation to reduce the rate of orbital recurrence, with the understanding that this treatment, while not definitively harmful, is of unproved benefit. She was also referred to the medical oncology service for systemic therapy and has begun an experimental treatment protocol using interferon alfa. Systemic chemotherapy is currently under consideration.

Comment

Options for the management of choroidal melanoma include observation, laser photocoagulation, transpupillary thermotherapy, charged particle radiotherapy, brachytherapy, local resection, and enucleation. Argon laser photocoagulation is typically used as an adjunct to other treatments, but in select cases has been used as primary therapy for choroidal melanoma. Typically, photocoagulation is reserved for small tumours (less than 3–4 mm in thickness and less than 10 mm in diameter) that do not radiate close to the fovea and/or the optic disc in eyes with good vision. Because the level of tumour necrosis with laser photocoagulation is shallow (0.2–0.8 mm), multiple treatments are often necessary. Therefore, the greatest challenge to successful photocoagulative therapy in choroidal melanomas is determining when the tumour has been fully ablated. TTT shares the characteristics that photocoagulation has over radiotherapy, including the more rapid visible reduction of tumour size, the relative sparing of adjacent normal tissue, and the convenience and economy of an outpatient procedure. In contrast with the shallow penetration of the argon laser, however, TTT employs near infrared light to produce a 3–9 mm depth of tumour necrosis. The promise of this treatment and the spurred investigation into its use as a primary treatment for small posterior choroidal melanomas with encouraging early results. It has been reported that recurrences occur following apparently successful photocoagulation or TTT because invisible nests of malignant cells can infiltrate the sclera, a histologically documented phenomenon. The presented case serves as a reminder that this possibility is not trivial. Extrascleral extension, presumably from tumour out of reach of initial argon photocoagulation and subsequent TTT, resulted in a requirement for aggressive local surgical therapy, photocoagulation therapy, and adjuvant systemic therapy to reduce the risk of metastatic disease. The unusual degree of extraocular extension for a small melanoma also raises the possibility that either photocoagulation or, more likely, TTT produced some reduction in scleral integrity allowing focal egress of tumour cells. Reports of complications following argon laser therapy are likely to become rarer because advances in modern photocoagulation have made primary photocoagulation an uncommon treatment. The use and investigation of TTT, however, continue to increase and the risks for extrascleral extension remain undefined.

T Tsai, J M O’Brien
Ocular Oncology Unit, Department of Ophthalmology, University of California, San Francisco, California, USA

R Engstrom, B R Straatsma
Jules Stein Eye Institute, University of California, Los Angeles, California, USA

Correspondence to: Joan O’Brien, MD, Ocular Oncology Unit, UCSF Department of Ophthalmology, 10 Kirkham Street, Box 0720, San Francisco, CA 94143, USA; alejta@itsa.ucsf.edu

Accepted for publication 29 August 2001

References


Macular infarction after intravitreal amikacin: mounting evidence against amikacin

Retinal toxicity attributable to intravitreal use of aminoglycosides for endophthalmitis has been reported. Campochiaro and Conway reported 101 cases of retinal damage due to intravitreal aminoglycosides.1 Amikacin, an aminoglycoside, is in widespread use in the United Kingdom for the treatment of Gram negative organisms in endophthalmitis. We report a case of macular toxicity following the use of intravitreal amikacin for postoperative endophthalmitis, outlining mechanisms of retinal toxicity, and offer alternatives to amikacin. We believe that enough evidence now exists to support a change in the current Royal College of Ophthalmologists’ endophthalmitis treatment guidelines that are based on the Endophthalmitis Vitrectomy Study.2

Case report

A 69 year old white woman presented 1 day after an uneventful right phacoemulsification and intraocular lens implantation with a vision of counting fingers (CF), a relative afferent pupil defect, hypopyon with anterior chamber fibrin, and normal intraocular pressure. We were unable to visualise the fundus although a red reflex was noted. Ultrasound examination showed patchy increased vitreous reflectivity with a flat retina and choroid. Pars plana vitreous tap of 0.2 ml was performed followed by injection of 1 mg/0.1 ml of vancomycin and 0.4 mg/0.1 ml of amikacin. Sterile dilution was conducted with intravitreal amikacin. The globe never became tense. The ocular inflammation resolved on a daily regimen of oral prednisolone 60 mg, oral ciprofloxacin 750 mg four times daily, topical dexamethasone 0.3% hourly, topical dexamethasone 0.1% 2 hourly, and topical atropine 1% once daily. Vision however remained CF because of angiographically proven macular ischaemia and vascular occlusion (Figs 1 and 2). There was no microbiological growth from the vitreous sample.

www.bjophthalmol.com
we support a change in current UK treatment guidelines. Choices will remain controversial until the incidence of toxicity for both amikacin and ceftazidime is determined by a prospective randomised controlled study; however, on the evidence currently available we suggest that ceftazidime should replace amikacin as the first line agent of choice against Gram negative organisms in postoperative endophthalmitis.

G Galloway, A Ramsay, K Jordan, A Vivian
Department of Ophthalmology, West Suffolk Hospital, Bury St Edmunds, IP33 2GZ, UK
Correspondence to: Mr Gavin Galloway; gavg@doctors.org.uk
Accepted for publication 22 August 2001

References

Spontaneous invovlution of retinal and intracranial arteriovenous malformation in Bonnet-Dechaume-Blanc syndrome

Intracranial arteriovenous malformations are capable of spontaneous regression. There are also numerous recorded events of vascular remodelling, thrombosis, and autoinvolvement in retinal arteriovenous malformations. This report documents a self obliterated retinal arteriovenous malformation in a patient with Bonnet-Dechaume-Blanc syndrome who developed neurological symptoms due to spontaneous regression of the intracranial component of the anastomosus malformation.

Case report
A 12 year old man from Guam was evaluated for a history of right parietal headaches for several months and acquired temporal hemianopia in the left eye. He had a history of blindness in the right eye from early childhood, and had recently become aware of a temporal hemianopia in the left eye.

Visual acuity was no light perception in the right eye and 20/20 in the left eye. The right pupil was unreactive to light. The left pupil was sluggishly reactive and there was a right afferent pupillary defect. Slit lamp examination showed conjunctival venous engorge- ment in the right eye. Retinal examination disclosed white, sclerotic major retinal vessels, with no evidence of retinal vascular perfusion in the right eye (Fig 2). The major retinal vessels were surrounded by non-perfused clusters of white, racemose, telangiectatic, vessels (Fig 1). The left optic nerve showed band atrophy with corresponding nerve fibre layer dropout but no other retinal abnormality.

Magnetic resonance imaging showed numerous vascular channels permeating the right basal ganglia, anterior portion of the midbrain, prefrontal gyri, optic chiasm, and the right orbital. The deep hemispheric portion of the lesion showed surrounding oedema. CT scanning showed punctate and conglomerate calcifications in the malformation, as well as enlargement of the right optic canal. Cerebral angiography demonstrated an angiomatosus vascular malformation that permeated the basal ganglia as well as the optic chiasm region and extended into the right orbit (Fig 2). There was a relative lack of deep venous drainage in the chiasmatic region of the malformation, with diversion to the Sylvian vein system and over the convexities to the sagittal sinus. The lack of hypertrophy in these draining venous channels, together with the

Figure 1 Fundus photograph showing diffuse posterior pole retinal cloudy swelling, cotton wool spots, and scattered intraretinal haemorrhages.

Figure 2 Fluorescein angiogram at 48 seconds showing diffuse macular arteriovenous occlusion with staining of the arteriolar walls along the inferior and superior arcades.

Comment
The rationale for amikacin use relates to the relatively high incidence of Gram negative isolates in endophthalmitis (6.4–26.2%) and the broad spectrum of action with low resistance offered by this agent. Amikacin has largely superseded gentamicin because of its perceived safety profile. Our case and others reported in the literature serve to notify clinicians of the serious retinal toxicity occurring with amikacin use, which is possibly a class related phenomenon.

Hypotheses for toxicity include dilution errors, raised post-injection intraocular pressure, concomitant use of high concentrations of subconjunctival amikacin, and variations in vitreous concentration. Local variation in concentration may play a part if the agent is directly injected into the posterior vitreous space instead of the gel itself. Another possibility for macular predilection is that this is the dependent part in the supine patient during pars plana injection.

Large studies offer alternatives to aminoglycosides on the basis of culture sensitivities. Suggestions include cefazidi-me, cefotaxime, and ciprofloxacin. Sensitivities of Gram negative organisms to ceftazi-dime range from 61% to 100% according to published studies. It appears that in most studies 2 mg (0.1 ml of 20 mg/ml solution) of ceftazidime has in vitro effectiveness equipotent to or greater than 0.4 mg amikacin. Primate studies have shown that intravitreal ceftazidime is non-toxic at doses of 2.25 mg. Cefazidime is already in clinical use in the United Kingdom. There have been no reported cases of retinal toxicity with intravitreal ceftazidime use in humans. With mounting evidence against amikacin we support a change in current UK treatment
regional oedema on magnetic resonance imaging, suggested a recent obstruction of vascular flow within the angiomatous malformation.

Comment

The syndrome of unilateral retinocephalic arteriovenous malformation was first described in 1937 by Bonnet et al. Six years later, Wyburn-Mason published his report in the English language. These congenital unilateral retinocephalic arteriovenous malformations may involve the visual pathways from the retina to the ipsilateral occipital cortex, and may involve the chiasm, hypothalamus, basal ganglia, midbrain, and cerebellum. Since these arteriovenous malformations are high flow systems in which veins are exposed to arterial blood pressures, they are susceptible to turbulent blood flow and to vessel wall damage which can lead to thrombosis and occlusion. ‘Over time, components of an angiomatic malformation can grow, haemorrhage, sclerosis, thrombose, and involute.’

Our patient had longstanding involvement of his retinal arteriovenous malformation, with new neurological symptoms resulting from thrombosis of the intracranial component of the tumour. Spontaneous occlusion of the major venous drainage within the deep cerebral hemisphere and optic chiasm may have caused headaches by producing regional oedema or by diverting flow to other venous structures. Since the major venous drainage within the malformation was already occluded at the time of presentation, no treatment was advised. The complex evolution of clinical signs in our patient underscores the need to distinguish disease progression from spontaneous involvement in symptomatic patients with Bonnet-Dechaume-Blanc syndrome.

Acknowledgement

Supported in part by a grant from Research to Prevent Blindness, Inc.

M C Brodsky
Department of Ophthalmology and Pediatrics, University of Arkansas for Medical Sciences, Little Rock, AR, USA

W F Hoyt
Departments of Ophthalmology, Neurology and Neurosurgery, University of California, San Francisco, CA, USA

Correspondence to: Michael C Brodsky, MD, Arkansas Children’s Hospital, 800 Marshall, Little Rock, AR 72202, USA

Acceptance for publication 29 August 2001

References


Glucoma

The latest issue of Community Eye Health (No 39) discusses the glucomas, with an editorial by Professor Gordon J Johnson, director of the International Centre for Eye Health. For further information please contact: Journal of Community Eye Health, International Centre for Eye Health, Institute of Ophthalmology, 11–43 Bath Street, London EC1V 9EL, UK (tel: +44 (0)20 7680 6910; email: eyeresource@ucl.ac.uk; website: www.jchc.co.uk). Annual subscription (4 issues) UK£25/US$40. Free to workers in developing countries.

International Centre for Eye Health

The International Centre for Eye Health has published a new edition of the Standard List of Medicines, Equipment, Instruments and Supplies (2001) for eye care services in developing countries. It is compiled by the Task Force of the International Agency for the Prevention of Blindness. Further details: Sue Stevens, International Centre for Eye Health, 11–43 Bath Street, London EC1V 9EL, UK (tel: +44 (0)20 7680 6910; email: eyeresource@ucl.ac.uk).

Second Sight

Second Sight, a UK based charity whose aims are to eliminate the backlog of cataract blind in India by the year 2020 and to establish strong links between Indian and British ophthalmologists, is regularly sending volunteer surgeons to India. More can be found at the charity website (www.secondsight.org.uk) or by contacting Dr Lucy Mathen (lucymathen@yahoo.com).

Specific Eye ConditionS (SPECS)

Specific Eye Conditions (SPECS) is a not for profit organisation which acts as an umbrella organisation for support groups of any conditions or syndrome with an integral eye disorder. SPECS represents over fifty different condition support groups and includes CMV retinitis and other HIV related ophthalmologic diseases. The fellowships each include $US 5000. Deadline for application is 31 March 2002.

Details for abstracts should be sent to the SPECS contact: Kay Parkinson, SPECS Development Officer (tel: +44 (0)1803 524238; email: k@eyeconditions.org.uk; www.eyeconditions.org.uk).

Joachim Kuhlmann Fellowship for Ophthalmologists 2002

In honour of its founder’s memory, the Joachim Kuhlmann AIDS-Stiftung, Essen, Germany, is sponsoring two fellowships for ophthalmologists at a well known institute, who want to train in CMV-retinitis and other HIV related ophthalmologic diseases. The fellowships each include $US 5000. Deadline for application is 31 March 2002.

Details including a CV and publications list should be sent to the National Kuhlmann AIDS-Foundation, Bismarckstr. 55, 45128 Essen, Germany. Further information is available at www.jk-AIDS-stiftung.de.

12th Meeting of the European Association for the Study of Diabetic Eye Complications (EASDEC)

The 12th meeting of the EASDEC will be held on 24–26 May 2002 in Udine, Italy. The deadline for abstracts is 15 February 2002. Three travel grants for young members (less than 35 years of age at the time of the meeting) are available. For information on the travel grants, please contact Prof CD Agardh, President of EASDEC, Malmö University Hospital, SE-205 02 Malmö, Sweden (tel: +46 40 33 10 16; fax: +46 40 33 73 66; email: carl.david.agardh@endo.mas.lu.se). Further details: NORD EST CONGRESSI, Via Aquilea, 21–33100 Udine, Italy (tel: +39 343 213191; fax: +39 0432 50687; email: nordest.congressi@ud.net.uno.it).

International Society for Behcet’s Disease

The 10th International Congress on Behcet’s Disease will be held in Berlin 27–29 June 2002. Further details: Professor Ch Zouboulis (email: zoubbere@zedat.fu-berlin.de).

Singapore National Eye Centre 5th International Meeting

The Singapore National Eye Centre 5th International Meeting will be held on 3–5 August 2002 in Singapore. Further details: Ms Amy Lim, Organising Secretary, Singapore National Eye Centre, 11 Third Hospital Avenue, Singapore 168751 (tel: (65) 322 8374; fax: (65) 227 7290; email: Amy.Lim@snc.com.sg).

BEAVRS Meeting

The next BEAVRS meeting will be held in the Dalmahoy Hotel near Edinburgh on 31 October to 1 November 2002. Further details: Susan Campbell, Medical Secretary, Garnetval Hospital (email: susan.j.campbell.wg@northglasgow.scot.nhs.uk).

NOTICES

The XVIth International Congress of Ophthalmology will be held on 21–25 April 2002 in Sydney, Australia. Further details: Congress Secretariat, C/- ICM斯 Australia Pty Ltd, GPO Box 2609, Sydney, NSW 2001, Australia (tel: +61 2 9241 1476; fax: +61 2 9251 3552; email: ophthalm@icmsaust.com.au; website: www.ophthalmology.aust.com).

www.bjophthalmol.com
Henoch-Schonlein purpura with bilateral central retinal artery occlusion

T-T Wu, S-J Sheu, L-C Chou, T-T Wu, S-J Sheu and S-J Sheu

**Br J Ophthalmol** 2002 86: 351-352
doi: 10.1136/bjo.86.3.351

Updated information and services can be found at:
http://bjo.bmj.com/content/86/3/351

**These include:**

**References**
This article cites 5 articles, 0 of which you can access for free at:
http://bjo.bmj.com/content/86/3/351#BIBL

**Email alerting service**
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/